POLYDOX (POLY-MVA) CANCER
Fateh Srajeldin N.D.*
Physical Description: Polydox is a dark, almost
reddish brown liquid. It is packaged in 120 mls., and 240 mls., dark
bottles.
Chemical Description: A trimeric palladium compound
with properties of a nucleotide reductase.
DESCRIPTION
Polydox is known in the United States and Canada by the
name of Poly-MVA, a compound developed and approved for patients use in
Mexico. It is a synthetic nucleotide reductase with a natural chemical
configuration.
In addition to palladium and its salts, this unique and
patented compound contains thiamine and complexes of
thiamine-palladium-lipoic and cyanocobalamin (synthetic B12).
The lipoic acid fraction includes cations such as sodium,
potassium, magnesium, calcium, ammonia, zinc and other necessary trace
minerals. Crystallographic studies indicate that polydox forms a trigonal
prism representative of an octa-coordinate molecule.
The inventor, Dr. Merrill Harnett, discovered that lipoic
acid as used in the present formula in Polydox is highly specific for
transferring electron energy from a normal metabolic hydrogen carrier to
nucleic acids.
CLINICAL PHARMACOLOGY
The substitution of palladium for platinum produced major
benefits in therapeutic uses. Platinum has a long history of uses as a
chemotherapeutic agent which is known to be very toxic. Palladium, on the
other hand, is a transition metal of Group VIII of the chemical elements
periodic table which not toxic and it.
Whereas platinum compounds destroy certain cell's,
palladium as used in this invention takes a different approach to
tumorigenesis.
The relatively new science of molecular biology indicates
altered DNA as a principal factor in malignant development. Altered genes
produce abnormal protein substances.
A major factor in the success of Polydox has been to
provide an electron energy transfer mechanism from normal metabolic hydrogen
carriers to nucleic acids. Nucleic acids are the main constituents of DNA.
Polydox induces energy dependant conformational changes in DNA or RNA as a
result of the reduced state it induces in the nucleotide.
An Antioxidants
It is postulated that as oncongenesis is related to
farnesyl transfer. Blocking this transfer allows the normalized transfer of
electron charges to occur from the lipid part of the membrane. In addition
to its energy transfer properties, Polydox is an effective anti-oxidant.
Polydox acts synergistically with other antioxidants and potentiates there
effects.
Cancerous cells, cells with altered DNA, are characterized
as unable to produce adequate water as a product of a normal metabolism.
Polydox stimulates the production of intracellular water thus driving the
cell toward normalcy.
Indications
Polydox as indicated in conditions of abnormal rapid cell
division such as cancerous cells. Extensive use of Polydox (over three
years) by Dr. Falk, oncologist in Canada, found no effect on the normally
rapidly dividing cells such as hair, lung, and intestine of marrow cells.
Patients with abnormally dividing cells, such as cancerous cells, were in
many cases benefitted.Non-malignant uses Anecdotal reports indicate unusual
success in the treatment of nonmalignant conditions such as fibromatosis,
psoriasis, and Alzheimer's disease.
There is a demonstrated tonic effect which has been widely
reported especially in older patients who suffer from fatigue, and loss of
appetite. This tonic effect of increased energy is postulated to be caused
by the activation of B12 and thiamin molecules whose effect has been
potentiated by the configuration of the new molecule in Polydox. This report
does not discuss the many functions and uses of these vitamins except to say
that they seem to be more active in the Polydox form. It is possible that
some of the beneficial neurological changes reported in multiple sclerosis,
central nervous system malignant tumors, and Alzheimer are due to the active
vitamins contained in Polydox.
There is some evidence that palladium may be an essential
trace metal. It appears that palladium has an effect on the structure of
certain bio-inorganic molecules and thus induces some changes on their
function. For further information the reader is referred to Metals on
Medicine and the word of R.Lampeka of the Department of Chemistry, Kiev
University and H. Wanjek of the Institute of Inorganic Chemistry, Munich
University.
USES IN MALIGNANT CONDITIONS
Polydox was invented with the purpose of finding a
non-toxic treatment for cancer. The altered gene was known as the proximate
cause of malignant transformations. The nucleotide was identified as the
basic molecular structures which controlled cell division and replication.
Enzymes were known to effect DNA repair and thus Dr. M. Garnett focused his
research on the nucleotide reductase's with the result of the development of
Polydox.
The concept of repairing the altered gene as a treatment
for cancer by using semisynthetic compound is a major departure from the
current concept of destructive treatments.
Brain tumors: the most dramatic responses were noted
with brain tumors. Rapid success has been documented on cases of
Glioblastomas. Even in the late stages with extensive symptoms of partial
paralysis, memory changes and ambulatory abnormalities there was a quick and
prolonged return to normal function.
Lung cancers: especially broncho genic arcinomas are
notoriously difficult to treat. Polydox use has substantially increased life
span. Excess pleural fluid is a complication, but can be reduced by avoiding
antibiotic use and by reducing the dose of Polydox.Some clinicians report
success by augmenting oral use with mist inhalation of the Polydox.
Ovarian cancers respond well to oral use of Polydox.
Long term success in this cancer and others is related to long term use of
Polydox.
Breast cancers: whether they are hormone sensitive
or not seen to respond to Polydox. Late stages with an extensive bone
metastasis have reported resolution of the bone loss and reduction of pain.
Megace, an anti-estrogen, augments the benefit.
Symptom relief
Any cancer patient who had suffered pain, anorexia or
weight loss may benefit from a 30 day supervised trial by a physician. Most
cancer patients report improved appetite and weight gain with the first few
days of beginning Polydox. The question of how Polydox reduces pain in
cancer is being studied and requires more investigation. One theory suggests
that as the tumor cells are destroyed, the smaller mass reduces pressure
caused by chest pain.
As an adjuvant
The original clinical work in vivo in Canada proved that
Polydox was very safe. In over two years of use it produced no side effects
or undesirable reactions. Its main use was as an adjuvant.
It was used in Canada by an oncologist, Dr. Falk, usually
in conduction with standard chemotherapy. He reported benefit using this
combination in the majority of patients. The benefits he reported included
pain reduction or pain control, increased energy, improve appetite and
weight gain.
Some patients are still using low doses of Polydox and have
no apparent signs of cancer after two to three years of its use.
RADIOTHERAPY
The strong antioxidant effects of Polydox are probably
responsible for the increased benefit of radiation treatments. It is
postulated that
(1) Polydox protects surrounding tissues,
thereby causing less post-irradiation damage.
(2) Polydox sensitizes the malignant cell making it more responsive
to lower doses of radiation. There effects require more controlled studies.
Toxicity studies
Animal studies and the studies in Canada proved the very
safe nature of Polydox. Toxicity studies were performed which met the
toxicity standards of the FDA . Extensive intravenous and oral toxicity
studies by testing agent Pharmakon USA, PO BOX 609, Waverly, penn. Reported:
"Based on the results from the Acute Intravenous Toxicity
Study in mice the test article, synthetic Reductase 25mg/ml is considered to
be non-toxic when administered as an intravenous injection as 15.0ml/kg."
"Based upon the results from the Acute Oral Toxicity study
in Mice (14 days), the estimated acute aral LD50 for combined sexes for the
Synthetic Reductase (25 mg/ ml) is determined to be greater than 5000mg/kg".
Mitogen tests are routinely performed by using
Ames/Salmonella Assay. "The results of synthetic DNA reductase were
negative."
CONTRADICTIONS
Current studies revealed no known contradictions.
Adverse reactions
There have been reports in lung cancers of increased
production of pleural effusions when using Polydox. This has been associated
with the concomitant use of antibiotics. It is recommended that when Polydox
is used in pulmonary malignancies that antibiotics be withheld under the
prescribing physician's supervision. If fluid forms then reduce the dose of
Polydox. Fluid production is common in non-small cell carcinomas with or
without Polydox.More studies are required to establish the mechanisms of
pleural effusions.
DOSAGE AND ADMINISTRATION
As a Tonic or Nutritional Aid, Poly-nucleotide (Polydox) is
a complex of valuable minerals and vitamins. Its strong antioxidant effects
would be beneficial in slowing the aging cellular process, and reducing the
disease causing effects of cell damage as a response to the excessive
presence of free radicals. It can be used to potentiate the actions of other
antioxidants. It has been shown to increase appetite and improve energy
levels in the middle aged and elderly.
Tonic Dose: 3 to 10 drops per day mixed in water or juice.
In cancer patients:
Week one and weeks two: take two tea spoons three time a day after meals
plus two tea spoons before bed time. Week three and weeks four: take two tea
spoons three time a day after meals. Thereafter: take two tea spoons Morning
and evening.
CHRONIC AND DEBILITATING DISEASES
Starting dose in seriously ill patients usually begin with
40 mg daily for up to one week taken in divided doses of 10 mg four times
daily. It can be taken mixed in water, juice or a hot drink. Second week use
20 mg per day or 5 mg four times daily. Third week use 10 mg per day or 5 mg
twice daily. From the fourth week and thereafter use 5 mg daily.
This novel semisynthetic compound is extremely safe and
easy to be used under the prescribing physician's directions. It can be
considered as a cellular or DNA nutrient. The manufacturer states that the
not toxic B12 contained in the Polydox is the only adduct to nucleotide.
This summary was prepared by Lawrence H. Taylor, M.D. based
upon his observations and reports from other physicians and from the
producers. This is a new compound. Its properties and characteristics are
under active investigation in the United States and Mexico. The manufacturer
is not responsible for the statements contained herein.
CLINICAL RESEARCH PROJECT - POLYDOX
A product of Garnett-McKeen
STATEMENT OF PURPOSE
to meet non-IND FDA requirements permitting Polydox to be
shipped and used in Mexico for human clinical trial.
INTRODUCTION
Polydox as the name given to a novel compound recently
patented. The chemical description and some of the chemical properties are
described in the patent and will not be reviewed here. Biochemical
investigations now in progress under the direction of Garney-McKeen may
indicate that this compound activates intracellular receptors.
Theoretically this activation has a minimal or no
measurable effect on normal cells, but drives to destruction cells with
altered (malignant) genetic changes.
Currently most cancer chemotherputics when used in terminal
states diminish the quality of life while providing various degrees of
remission. It is believed that Polydox may encourage tumor remission with
minimal effect or deterioration of quality of life.
RESEARCH PURPOSE
Extensive studies of this compound in Canada indicate that
its use in humans by intravenous, intramuscular or oral routes is safe even
in larger than therapeutic dosages. Animal studies have reconfirmed its
safety.
The questions to be answered by this clinical study are:
1. Objective findings. Does the oral administration
of Polydox to terminal cancer patients induce measurable:
a)
remission in tumor size?
b) pain relief as measured by
reduction in pain medication?
c) change in appetite and weight gain?
2.Subjective reports. Does the terminal patient
report an improvement in energy, well being, ect...?
3.Identify deleterious drug interactions,
sensitivities or allergic responses and contradictions to the use of this
compound.
SPECIAL DOCTOR'S INSTRUCTIONS
POLYDOX HAS NO KNOWN TOXIC EFFECTS IN ANIMALS OR
HUMANS. IT CAUSES NO INJURY TO NORMAL CELLS.
Changing cancer cells to more normal functions is one
effect of POLYDOX. It does this by encouraging the cell to produce water
which is a natural function in normal cells. If water is produced the cell
can rid itself of unwanted toxic substances and it resumes a more normal
function. Another effect is the death of the cell. In some cases the cancer
cell is unable to produce water under the influence of POLYDOX and dies.
POLYDOX is not considered toxic.
The rapid death of abnormal
(cancer) cells can cause low grade fever, and flu-like symptoms.
If these occur:
The dose of POLYDOX should
be reduced, but do not stop its use.
Increase water intake to at least 6 glasses per day.
Coffee enemas may reduce these symptoms.
Cancer takes many years to develop. It takes many months
for the body to regain control. Therefore it is necessary to continue
treatment for extended periods of time. Continue the use of POLYDOX in low
doses such as 5 drops daily in water. Increase the dose if the tumor becomes
active.
During this healing period the patient should avoid
exposure to insecticides, germicides, and tobacco in any form. Nutritious
food, a clean environment and mental tranquility are necessary.
POLYDOX may inactivated EDTA chelation treatments because
of its strong mineral content.
Steady improvement is the most often reported result. Some
types of cancer respond rapidly. Anecdotal reports are valuable, but do not
constitute scientific proof. To aid us in the scientific study of POLYDOX we
want to follow your progress.
